Literature DB >> 32259216

Treatment for Advanced Soft Tissue Sarcoma: An Informative Neutral Trial.

Christina L Roland1, Sandra L Wong2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32259216      PMCID: PMC7605815          DOI: 10.1001/jama.2020.0567

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  FDA Approval and Regulation of Pharmaceuticals, 1983-2018.

Authors:  Jonathan J Darrow; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

2.  Reform at the FDA-In Need of Reform.

Authors:  Joshua M Sharfstein
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

3.  Adriamycin: a new effective agent in the therapy of disseminated sarcomas.

Authors:  R S Benjamin; P H Wiernik; N R Bachur
Journal:  Med Pediatr Oncol       Date:  1975

4.  Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.

Authors:  William D Tap; Andrew J Wagner; Patrick Schöffski; Javier Martin-Broto; Anders Krarup-Hansen; Kristen N Ganjoo; Chueh-Chuan Yen; Albiruni R Abdul Razak; Alexander Spira; Akira Kawai; Axel Le Cesne; Brian A Van Tine; Yoichi Naito; Se Hoon Park; Alexander Fedenko; Zsuzsanna Pápai; Victoria Soldatenkova; Ashwin Shahir; Gary Mo; Jennifer Wright; Robin L Jones
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

5.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

Review 6.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

Authors:  Padmanee Sharma; Klaus Wagner; Jedd D Wolchok; James P Allison
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

7.  ANNOUNCE prompts questions over the Accelerated Approval process.

Authors: 
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

Review 8.  Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.

Authors:  Bishal Gyawali; Spencer Phillips Hey; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.